ESTRO meets Asia 2024 - Abstract Book

S263

Interdisciplinary – SBRT

ESTRO meets Asia 2024

The preliminary results of the PRaG 3.0 regimen demonstrate promising efficacy and manageable safety profiles, suggesting that this treatment plan could be a viable salvage therapy option for patients with HER2-expressing advanced solid tumors, irrespective of HER-2 expression levels. It also potentially enhances the synergistic effect of radiotherapy combined with immunotherapy. However, further validation in a larger patient cohort is required.

Keywords: antibody-drug conjugate, HER-2-expressing

References:

1.Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020;25(20):4764

2. Sheng X, Yan X, Wang L, et al. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021;27(1):43-51 3. Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41(11):1173-1182

4.Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect? Biochem Pharmacol. 2016;102:1-6

5. Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Deliv. 2022;29(1):1335-1344

6. Hingorani DV, Allevato MM, Camargo MF, et al. Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy. Nat Commun. 2022;13(1):3869

7. Kong Y, Zhao X, Xu M, et al. PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study. Front Immunol. 2022;13:952066

8. Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020;70(2):125-137

178

Proffered Paper

Impact of Dose in Oligometastatic Liver SABR: A UK Single-Centre Experience

Zhu Chuen Oong 1 , Geok Gee Yeo 1 , Shaarven Kumar 1 , Andrew Brocklehurst 1 , Rachael Hall 2 , Zoe Turpin 2 , Philip Whitehurst 2 , Laura Forshaw 3 , Clare Triffitt 3 , Amarjot Chander 4 , Prakash Manoharan 4 , Carmel Anandadas 1 , David Woolf 1 , Laura Forker 1 , Ganesh Radhakrishna 1 1 Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 2 Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, United Kingdom. 3 Radiotherapy, The Christie NHS Foundation Trust, Manchester, United Kingdom. 4 Clinical Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom